Figure1 (Atorvastatin Figure1)
This text provides information about the effect of Atorvastatin 10 mg/day on the cumulative incidence of non-fatal myocardial infarction or coronary heart disease death in a study referred to as ASCOT-LLA. Figure 1 shows a graph depicting the cumulative incidence (%) over a period of 3.0 to 3.5 years. The graph compares the outcomes of patients treated with Atorvastatin (represented by the label "Atorvastatin") versus those who received a placebo (represented by the label "Placebo"). The graph suggests that Atorvastatin may have a beneficial effect in reducing the cumulative incidence of these cardiovascular events. The hazard ratio (HR) for Atorvastatin compared to placebo is reported as 0.64 with a 95% confidence interval from 0.50 to 0.83, and a p-value of 0.0005.*